Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 47

1.

American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer.

Loblaw DA, Mendelson DS, Talcott JA, Virgo KS, Somerfield MR, Ben-Josef E, Middleton R, Porterfield H, Sharp SA, Smith TJ, Taplin ME, Vogelzang NJ, Wade JL Jr, Bennett CL, Scher HI; American Society of Clinical Oncology.

J Clin Oncol. 2004 Jul 15;22(14):2927-41. Epub 2004 Jun 7. Erratum in: J Clin Oncol. 2004 Nov 1;22(21):4435.

PMID:
15184404
[PubMed - indexed for MEDLINE]
2.

Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline.

Loblaw DA, Virgo KS, Nam R, Somerfield MR, Ben-Josef E, Mendelson DS, Middleton R, Sharp SA, Smith TJ, Talcott J, Taplin M, Vogelzang NJ, Wade JL 3rd, Bennett CL, Scher HI; American Society of Clinical Oncology.

J Clin Oncol. 2007 Apr 20;25(12):1596-605. Epub 2007 Apr 2. Review.

PMID:
17404365
[PubMed - indexed for MEDLINE]
3.

Endocrine treatment of prostate cancer.

Tammela T.

J Steroid Biochem Mol Biol. 2004 Nov;92(4):287-95. Epub 2004 Dec 31. Review.

PMID:
15663992
[PubMed - indexed for MEDLINE]
4.

[Androgen deprivation for advanced prostate cancer].

Heidenreich A, Pfister D, Ohlmann CH, Engelmann UH.

Urologe A. 2008 Mar;47(3):270-83. doi: 10.1007/s00120-008-1636-2. Review. German.

PMID:
18273599
[PubMed - indexed for MEDLINE]
5.

The evolving role of hormone therapy in advanced prostate cancer.

Dreicer R.

Cleve Clin J Med. 2000 Oct;67(10):720-2, 725-6. Review.

PMID:
11060958
[PubMed - indexed for MEDLINE]
6.

Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma.

Samson DJ, Seidenfeld J, Schmitt B, Hasselblad V, Albertsen PC, Bennett CL, Wilt TJ, Aronson N.

Cancer. 2002 Jul 15;95(2):361-76. Review.

PMID:
12124837
[PubMed - indexed for MEDLINE]
Free Article
7.

American Society of Clinical Oncology endorsement of the Cancer Care Ontario Practice Guideline on nonhormonal therapy for men with metastatic hormone-refractory (castration-resistant) prostate cancer.

Basch EM, Somerfield MR, Beer TM, Carducci MA, Higano CS, Hussain MH, Scher HI; American Society of Clinical Oncology.

J Clin Oncol. 2007 Nov 20;25(33):5313-8. Epub 2007 Oct 9. Review.

PMID:
17925542
[PubMed - indexed for MEDLINE]
8.
9.

Pharmacoeconomics of available treatment options for metastatic prostate cancer.

Zeliadt SB, Penson DF.

Pharmacoeconomics. 2007;25(4):309-27. Review.

PMID:
17402804
[PubMed - indexed for MEDLINE]
10.

Current topics and perspectives relating to hormone therapy for prostate cancer.

Suzuki H, Kamiya N, Imamoto T, Kawamura K, Yano M, Takano M, Utsumi T, Naya Y, Ichikawa T.

Int J Clin Oncol. 2008 Oct;13(5):401-10. doi: 10.1007/s10147-008-0830-y. Epub 2008 Oct 23. Review.

PMID:
18946750
[PubMed - indexed for MEDLINE]
11.

Androgen deprivation therapy for prostate cancer.

Sharifi N, Gulley JL, Dahut WL.

JAMA. 2005 Jul 13;294(2):238-44. Review.

PMID:
16014598
[PubMed - indexed for MEDLINE]
12.

[Oncoforum in urology and review of the literature].

Hennequin C.

Cancer Radiother. 2008 Sep;12 Spec No 2:1-8. doi: 10.1016/S1278-3218(08)73947-7. Review. French.

PMID:
18823869
[PubMed - indexed for MEDLINE]
13.

Medical therapy of prostate cancer. A review.

Roscigno M, Sangalli M, Mazzoccoli B, Scattoni V, Da Pozzo L, Rigatti P.

Minerva Urol Nefrol. 2005 Jun;57(2):71-84. Review.

PMID:
15951731
[PubMed - indexed for MEDLINE]
14.

Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes.

Cookson MS, Aus G, Burnett AL, Canby-Hagino ED, D'Amico AV, Dmochowski RR, Eton DT, Forman JD, Goldenberg SL, Hernandez J, Higano CS, Kraus SR, Moul JW, Tangen C, Thrasher JB, Thompson I.

J Urol. 2007 Feb;177(2):540-5. Review.

PMID:
17222629
[PubMed - indexed for MEDLINE]
15.

Early versus deferred androgen suppression therapy for patients with lymph node-positive prostate cancer after local therapy with curative intent: a systematic review.

Kunath F, Keck B, Rücker G, Motschall E, Wullich B, Antes G, Meerpohl JJ.

BMC Cancer. 2013 Mar 19;13:131. doi: 10.1186/1471-2407-13-131. Review.

PMID:
23510155
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

[Therapeutic options in advanced cancer of the prostate].

Schmid HP, Bitton A.

Praxis (Bern 1994). 1997 Oct 29;86(44):1734-9. Review. French.

PMID:
9446174
[PubMed - indexed for MEDLINE]
17.

The selection of hormonal therapy in prostate cancer: who, when, and for how long?

Ryan CJ, Small EJ.

J Natl Compr Canc Netw. 2004 May;2(3):261-8. Review.

PMID:
19795609
[PubMed - indexed for MEDLINE]
18.

Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer.

Taylor LG, Canfield SE, Du XL.

Cancer. 2009 Jun 1;115(11):2388-99. doi: 10.1002/cncr.24283. Review.

PMID:
19399748
[PubMed - indexed for MEDLINE]
Free Article
19.

What implications do the tolerability profiles of antiandrogens and other commonly used prostate cancer treatments have on patient care?

Mason M.

J Cancer Res Clin Oncol. 2006 Aug;132 Suppl 1:S27-35. Review.

PMID:
16896883
[PubMed - indexed for MEDLINE]
20.

An overview of chemotherapy trials in localized and recurrent nonmetastatic prostate cancer.

Oh WK.

J Urol. 2004 Nov;172(5 Pt 2):S34-7; discussion S37. Review.

PMID:
15535440
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk